GEP20063860B - Chemically-modified human growth hormone conjugates - Google Patents
Chemically-modified human growth hormone conjugatesInfo
- Publication number
- GEP20063860B GEP20063860B GE5599A GEAP2002005599A GEP20063860B GE P20063860 B GEP20063860 B GE P20063860B GE 5599 A GE5599 A GE 5599A GE AP2002005599 A GEAP2002005599 A GE AP2002005599A GE P20063860 B GEP20063860 B GE P20063860B
- Authority
- GE
- Georgia
- Prior art keywords
- growth hormone
- human growth
- chemically
- modified human
- conjugate
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/61—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Endocrinology (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33190701P | 2001-11-20 | 2001-11-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GEP20063860B true GEP20063860B (en) | 2006-06-26 |
Family
ID=23295870
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GE5599A GEP20063860B (en) | 2001-11-20 | 2002-11-20 | Chemically-modified human growth hormone conjugates |
Country Status (25)
| Country | Link |
|---|---|
| EP (1) | EP1453859A2 (enExample) |
| JP (2) | JP2005525302A (enExample) |
| KR (2) | KR20050044858A (enExample) |
| CN (1) | CN1608079A (enExample) |
| AP (1) | AP2004003050A0 (enExample) |
| AU (1) | AU2002356990A1 (enExample) |
| BR (1) | BR0214451A (enExample) |
| CA (1) | CA2467731A1 (enExample) |
| CO (1) | CO5580794A2 (enExample) |
| EA (2) | EA008505B1 (enExample) |
| EC (1) | ECSP045114A (enExample) |
| GE (1) | GEP20063860B (enExample) |
| HR (1) | HRP20040448A2 (enExample) |
| HU (1) | HUP0500997A2 (enExample) |
| IL (1) | IL162031A0 (enExample) |
| IS (1) | IS7268A (enExample) |
| MA (1) | MA27544A1 (enExample) |
| MX (1) | MXPA04004809A (enExample) |
| NO (1) | NO20042182L (enExample) |
| OA (1) | OA13063A (enExample) |
| PL (1) | PL374354A1 (enExample) |
| RS (1) | RS53104A (enExample) |
| TN (1) | TNSN04090A1 (enExample) |
| WO (1) | WO2003044056A2 (enExample) |
| ZA (1) | ZA200403907B (enExample) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030171285A1 (en) * | 2001-11-20 | 2003-09-11 | Finn Rory F. | Chemically-modified human growth hormone conjugates |
| US6916962B2 (en) | 2001-12-11 | 2005-07-12 | Sun Bio, Inc. | Monofunctional polyethylene glycol aldehydes |
| US6956135B2 (en) | 2001-12-11 | 2005-10-18 | Sun Bio, Inc. | Monofunctional polyethylene glycol aldehydes |
| EP1507755A4 (en) * | 2001-12-11 | 2006-05-17 | Sun Bio Inc | NOVEL MONOFUNCTIONAL POLYETHYLENE GLYCOL ALDEHYDES |
| US7041855B2 (en) | 2001-12-11 | 2006-05-09 | Sun Bio, Inc. | Monofunctional polyethylene glycol aldehydes |
| MXPA04006855A (es) * | 2002-01-18 | 2005-04-19 | Biogen Idec Inc | Compuestos de polimeros de polialquileno y usos de los mismos. |
| GEP20074193B (en) | 2002-09-09 | 2007-09-10 | Nektar Therapeutics Al Corp | Water-soluble polymer alkanals |
| EP1591467A1 (en) * | 2002-09-09 | 2005-11-02 | Nektar Therapeutics Al, Corporation | Conjugate between a polyethylene glycol having a terminal alkanal group and a human growth hormone |
| US20040142870A1 (en) * | 2002-11-20 | 2004-07-22 | Finn Rory F. | N-terminally monopegylated human growth hormone conjugates, process for their preparation, and methods of use thereof |
| US20050281778A1 (en) * | 2003-03-28 | 2005-12-22 | Myung-Ok Park | Human growth hormone conjugated with biocompatible polymer |
| US7524813B2 (en) | 2003-10-10 | 2009-04-28 | Novo Nordisk Health Care Ag | Selectively conjugated peptides and methods of making the same |
| CN100580087C (zh) * | 2003-10-10 | 2010-01-13 | 诺和诺德医疗保健公司 | 肽的缀合 |
| CA2552043A1 (en) * | 2004-01-21 | 2005-08-04 | Novo Nordisk A/S | Transglutaminase mediated conjugation of peptides |
| WO2006069220A2 (en) | 2004-12-22 | 2006-06-29 | Ambrx, Inc. | Modified human growth hormone |
| MX2007002441A (es) * | 2004-08-31 | 2007-05-04 | Pharmacia & Upjohn Co Llc | Conjugados de hormona del crecimiento humana y polietilenglicol ramificado con glicerol, proceso para su preparacion y metodos de uso de los mismos. |
| GB2438982A (en) | 2004-12-22 | 2007-12-12 | Ambrx Inc | Compostions containing, methods involving, and uses of non-natural amino acids and polypeptides |
| US8080391B2 (en) * | 2004-12-22 | 2011-12-20 | Ambrx, Inc. | Process of producing non-naturally encoded amino acid containing high conjugated to a water soluble polymer |
| EP1850878A2 (en) | 2005-02-10 | 2007-11-07 | Novo Nordisk A/S | C-terminally pegylated growth hormones |
| ATE497975T1 (de) | 2005-04-18 | 2011-02-15 | Novo Nordisk As | Il-21-varianten |
| US8293708B2 (en) | 2005-08-30 | 2012-10-23 | Novo Nordisk Health Care A/G | Liquid formulations N-terminal serine of pegylated growth hormone |
| ATE500215T1 (de) * | 2005-11-08 | 2011-03-15 | Ambrx Inc | Beschleuniger für die modifikation nichtnatürlicher aminosäuren und nichtnatürlicher aminosäurepolypeptide |
| EP1968635B1 (en) | 2005-12-14 | 2014-09-17 | Ambrx, Inc. | Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides |
| WO2008003750A2 (en) * | 2006-07-07 | 2008-01-10 | Novo Nordisk Health Care Ag | New protein conjugates and methods for their preparation |
| CN101108895B (zh) * | 2006-07-19 | 2011-10-26 | 北京键凯科技有限公司 | 聚乙二醇乙醛衍生物及其与药物的结合物 |
| EP2091968A2 (en) | 2006-10-26 | 2009-08-26 | Novo Nordisk A/S | Il-21 variants |
| CL2008002399A1 (es) | 2007-08-16 | 2009-01-02 | Pharmaessentia Corp | Conjugado sustancialmente puro que posee una porcion polimerica, una porcion proteica (interferon alfa 2b) y un ligante alifatico de 1 a 10 atomos de carbono, util en el tratamiento de las hepatitis b o c. |
| JP5458416B2 (ja) * | 2008-04-03 | 2014-04-02 | バイオスティード ジーン エクスプレッション テック． カンパニー リミテッド | 二本鎖ポリエチレングリコール化成長ホルモン、その製造方法およびその使用 |
| CA3004716C (en) | 2008-04-29 | 2022-04-12 | Ascendis Pharma Endocrinology Division A/S | Pegylated recombinant human growth hormone compounds |
| KR101104574B1 (ko) * | 2008-05-14 | 2012-01-11 | 성균관대학교산학협력단 | 폴리에틸렌글리콜로 화학적으로 수식된 인간 성장 호르몬, 이의 제조방법 및 용도 |
| MX2011001167A (es) * | 2008-07-31 | 2011-04-12 | Pharmaessentia Corp | Conjugados peptido-polimero. |
| MX2011000847A (es) | 2008-08-06 | 2011-02-25 | Novo Nordisk Healthcare Ag | Proteinas conjugadas con eficacia prolongada in vivo. |
| RU2409669C9 (ru) * | 2008-08-18 | 2012-05-27 | ООО "Саентифик Фьючер Менеджмент" ("Scientific Future Management", "SFM") | Способ иммобилизации биологически активного вещества (бав) на носитель (варианты) и конъюгат бав-носитель, полученный данными способами |
| WO2010030366A2 (en) * | 2008-09-11 | 2010-03-18 | Nektar Therapeutics | Polymeric alpha-hydroxy aldehyde and ketone reagents and conjugation method |
| CN102292349B (zh) | 2009-01-22 | 2016-04-13 | 诺沃—诺迪斯克保健股份有限公司 | 稳定的生长激素化合物 |
| CN102612376A (zh) | 2009-08-06 | 2012-07-25 | 诺沃-诺迪斯克保健股份有限公司 | 具有延长的体内功效的生长激素 |
| SG181648A1 (en) | 2009-12-15 | 2012-07-30 | Ascendis Pharma As | Dry growth hormone composition transiently linked to a polymer carrier |
| MX345736B (es) | 2010-01-22 | 2017-02-14 | Novo Nordisk Healthcare Ag | Hormonas de crecimiento con eficacia in vivo prolongada. |
| US9211342B2 (en) | 2010-01-22 | 2015-12-15 | Novo Nordisk Healthcare Ag | Stable growth hormone compounds resistant to proteolytic degradation |
| KR20130115086A (ko) * | 2010-05-17 | 2013-10-21 | 세빅스 인코포레이티드 | 페길화된 c-펩티드 |
| EP2446898A1 (en) | 2010-09-30 | 2012-05-02 | Laboratorios Del. Dr. Esteve, S.A. | Use of growth hormone to enhance the immune response in immunosuppressed patients |
| EA019967B1 (ru) * | 2011-12-21 | 2014-07-30 | Общество С Ограниченной Ответственностью "Форт" (Ооо "Форт") | Ковалентный конъюгат полиэтиленгликоля с гормоном роста человека |
| CN105120887A (zh) | 2013-04-05 | 2015-12-02 | 诺和诺德保健股份有限公司 | 生长激素化合物制剂 |
| SI3215193T1 (sl) | 2014-11-06 | 2024-02-29 | Pharmaessentia Corporation | Dozirna shema za pegiliran interferon |
| KR20250059541A (ko) | 2014-11-18 | 2025-05-02 | 아센디스 파마 엔도크리놀로지 디비전 에이/에스 | 신규한 중합체성 hGH 프로드러그 |
| PT3220892T (pt) | 2014-11-21 | 2021-11-05 | Ascendis Pharma Endocrinology Div A/S | Formas de dosagem de hormona do crescimento de longa ação |
| MA41957A (fr) * | 2015-03-11 | 2018-02-28 | Nektar Therapeutics | Conjugués d'une fraction d'il-7 et d'un polymère |
| KR102443831B1 (ko) * | 2015-09-18 | 2022-09-15 | 고쿠리츠 다이가쿠 호징 미야자키 다이가쿠 | 장시간 작용형 아드레노메둘린 유도체 |
| JP7524206B2 (ja) | 2019-03-04 | 2024-07-29 | アセンディス ファーマ エンドクライノロジー ディヴィジョン エー／エス | １日ごとのソマトロピンよりも優れた効力を有する長時間作用性成長ホルモン剤形 |
| CN114539384B (zh) * | 2020-11-19 | 2024-09-06 | 江苏众红生物工程创药研究院有限公司 | 聚乙二醇化长效生长激素及其制备方法和医药应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) * | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4904584A (en) * | 1987-12-23 | 1990-02-27 | Genetics Institute, Inc. | Site-specific homogeneous modification of polypeptides |
| EP0458064B1 (en) * | 1990-05-04 | 1998-02-25 | American Cyanamid Company | Stabilization of somatotropins by modification of cysteine residues |
| CA2101918A1 (en) * | 1991-03-18 | 1992-09-19 | Samuel Zalipsky | Hydrazine containing conjugates of polypeptides and glycopolypeptides with polymers |
| WO1993000109A1 (en) * | 1991-06-28 | 1993-01-07 | Genentech, Inc. | Method of stimulating immune response using growth hormone |
| NZ250375A (en) * | 1992-12-09 | 1995-07-26 | Ortho Pharma Corp | Peg hydrazone and peg oxime linkage forming reagents and protein derivatives |
| US5824784A (en) * | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
| DE851925T1 (de) * | 1995-09-21 | 2003-08-14 | Genentech Inc., San Francisco | Varianten des menschlichen wachstumshormons |
| WO2000042175A1 (en) * | 1999-01-14 | 2000-07-20 | Bolder Biotechnology Inc. | Methods for making proteins containing free cysteine residues |
| EP1012184B1 (en) * | 1997-07-14 | 2007-10-10 | Bolder Biotechnology, Inc. | Derivatives of growth hormone and related proteins |
| IL144361A0 (en) * | 1999-01-29 | 2002-05-23 | Hoffmann La Roche | Gcsf conjugates |
| AU2001289307A1 (en) * | 2000-04-06 | 2001-10-23 | Pharmacia Corporation | Chemically-modified myelopoietin conjugates |
| AU2002219021A1 (en) * | 2001-01-11 | 2002-07-24 | Maxygen Aps | Variant growth hormone molecules conjugated with macromolecular compounds |
-
2002
- 2002-11-20 WO PCT/US2002/037270 patent/WO2003044056A2/en not_active Ceased
- 2002-11-20 JP JP2003545691A patent/JP2005525302A/ja active Pending
- 2002-11-20 HU HU0500997A patent/HUP0500997A2/hu unknown
- 2002-11-20 OA OA1200400143A patent/OA13063A/en unknown
- 2002-11-20 GE GE5599A patent/GEP20063860B/en unknown
- 2002-11-20 KR KR1020047007708A patent/KR20050044858A/ko not_active Abandoned
- 2002-11-20 BR BRPI0214451-4A patent/BR0214451A/pt not_active IP Right Cessation
- 2002-11-20 AP APAP/P/2004/003050A patent/AP2004003050A0/en unknown
- 2002-11-20 EP EP02803695A patent/EP1453859A2/en not_active Withdrawn
- 2002-11-20 EA EA200400565A patent/EA008505B1/ru unknown
- 2002-11-20 MX MXPA04004809A patent/MXPA04004809A/es not_active Application Discontinuation
- 2002-11-20 RS YU53104A patent/RS53104A/sr unknown
- 2002-11-20 CA CA002467731A patent/CA2467731A1/en not_active Abandoned
- 2002-11-20 CN CNA028259289A patent/CN1608079A/zh active Pending
- 2002-11-20 EA EA200700431A patent/EA200700431A1/ru unknown
- 2002-11-20 IL IL16203102A patent/IL162031A0/xx unknown
- 2002-11-20 HR HR20040448A patent/HRP20040448A2/hr not_active Application Discontinuation
- 2002-11-20 KR KR1020077011730A patent/KR20070072924A/ko not_active Withdrawn
- 2002-11-20 AU AU2002356990A patent/AU2002356990A1/en not_active Abandoned
- 2002-11-20 PL PL02374354A patent/PL374354A1/xx unknown
-
2004
- 2004-05-17 IS IS7268A patent/IS7268A/is unknown
- 2004-05-19 MA MA27686A patent/MA27544A1/fr unknown
- 2004-05-20 EC EC2004005114A patent/ECSP045114A/es unknown
- 2004-05-20 CO CO04046633A patent/CO5580794A2/es not_active Application Discontinuation
- 2004-05-20 ZA ZA200403907A patent/ZA200403907B/en unknown
- 2004-05-20 TN TNP2004000090A patent/TNSN04090A1/fr unknown
- 2004-05-26 NO NO20042182A patent/NO20042182L/no not_active Application Discontinuation
-
2006
- 2006-07-14 JP JP2006193577A patent/JP2006321808A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| RS53104A (sr) | 2006-10-27 |
| EP1453859A2 (en) | 2004-09-08 |
| JP2005525302A (ja) | 2005-08-25 |
| BR0214451A (pt) | 2006-05-30 |
| JP2006321808A (ja) | 2006-11-30 |
| PL374354A1 (en) | 2005-10-17 |
| NO20042182L (no) | 2004-08-11 |
| EA200700431A1 (ru) | 2008-02-28 |
| CO5580794A2 (es) | 2005-11-30 |
| TNSN04090A1 (fr) | 2006-06-01 |
| CN1608079A (zh) | 2005-04-20 |
| MXPA04004809A (es) | 2004-08-11 |
| OA13063A (en) | 2006-11-10 |
| CA2467731A1 (en) | 2003-05-30 |
| ECSP045114A (es) | 2004-07-23 |
| WO2003044056A3 (en) | 2003-08-21 |
| IS7268A (is) | 2004-05-17 |
| AP2004003050A0 (en) | 2004-06-30 |
| HUP0500997A2 (en) | 2007-11-28 |
| EA008505B1 (ru) | 2007-06-29 |
| KR20050044858A (ko) | 2005-05-13 |
| KR20070072924A (ko) | 2007-07-06 |
| IL162031A0 (en) | 2005-11-20 |
| MA27544A1 (fr) | 2005-10-03 |
| AU2002356990A1 (en) | 2003-06-10 |
| EA200400565A1 (ru) | 2005-06-30 |
| WO2003044056A2 (en) | 2003-05-30 |
| HRP20040448A2 (en) | 2006-02-28 |
| ZA200403907B (en) | 2007-12-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GEP20063860B (en) | Chemically-modified human growth hormone conjugates | |
| CA2078347C (en) | Use of copper(ii) containing compounds to accelerate wound healing | |
| BG104484A (bg) | Сайт - специфично получаване на конюгати от полиетилен- гликол - grf | |
| BG100236A (en) | Sheared keratiocytic growth factor (kgf) of increased biological activity | |
| CY1106723T1 (el) | Ν-τελικα μονοπεγυλιωμενα συζευγματα ανθρωπινης αυξητικης ορμονης, διεργασιες για την παρασκευη τους και μεθοδοι χρησης αυτων | |
| DE69531332D1 (de) | Klonierung und Expression eines Gens, das Bryodin 1 aus Bryonia dioica kodiert | |
| UA66857C2 (uk) | КОН'ЮГАТ ПОЛІОЛ-<font face="Symbol">b</font>-ІНТЕРФЕРОН, СПОСІБ ОДЕРЖАННЯ КОН'ЮГАТУ ПОЛІОЛ-<font face="Symbol">b</font>-ІНТЕРФЕРОН ТА СПОСІБ ЛІКУВАННЯ ІНФЕКЦІЙНИХ ХВОРОБ, ПУХЛИН І АУТОІМУННИХ І ЗАПАЛЬНИХ ЗАХВОРЮВАНЬ | |
| CA2345027A1 (en) | Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility | |
| MXPA02006215A (es) | Metodo para preparar esteres de 1-benzotriazolil carbonato de poli(etilenglicol). | |
| AR044024A1 (es) | Mutante de sustitucion de la il-18 humana, composicion biologicamente activa que la comprende, su uso para preparar dicha composicion, metodo para prepararla y metodo para mejorar la farmacocinetica y farmacodinamica de dicha il-18 humana | |
| KR20070108535A (ko) | 폴리펩티드와 5당류의 접합체 | |
| WO2003061577A8 (en) | Polyalkylene glycol with moiety for conjugating biologically active compound | |
| AU5956398A (en) | Remedies for lymphocytic tumors | |
| WO2002055532A3 (en) | Variant growth hormone molecules conjugated with macromolecular compounds | |
| AU2005232475A1 (en) | Novel g-csf conjugates | |
| CA2444266A1 (en) | Use of bile acid or bile salt fatty acid conjugates | |
| EP1382352A1 (de) | Bisacyloxypropylcystein-Konjugate und deren Verwendung | |
| AR042103A1 (es) | Conjugados de hormona de crecimiento humana pegilados n- terminales y proceso para su preparacion | |
| BR0009472A (pt) | Antagonistas de lhrh com propriedades desolubilidade aperfeiçoadas | |
| KR890700606A (ko) | 생물학적 활성분자 | |
| BR0213821A (pt) | Conjugados de polìmero/peptìdeo timosina alfa 1 | |
| KR960000921A (ko) | 칼시토닌 유도체 및 그 용도 | |
| EP1763535B1 (de) | Mit einem organischem rest verbundenes polypeptid | |
| PT918795E (pt) | Droga antiangiogenica para tratar cancro artrite e retinopatia | |
| CA2498062A1 (en) | Conjugates of insulin-like growth factor binding protein-4 and poly(ethylene glycol) |